AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01815333
Drug: Feraheme
RxNorm normalized name: Feraheme
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6 mg of iron/kg (maximum 510 mg/dose) injected at a rate of 1 ml/sec (30 mg/sec) or slower after initial MRI.
Trial: NCT06222372
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic
Trial: NCT02245568
Drug: LMTM
RxNorm normalized name: LMTM
DrugBank: Hydromethylthionine mesylate (DB16899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial LMTM dose was 200 mg/day (one 100-mg tablet twice daily), except in subjects with bvFTD who were taking a reduced dose (i.e., 100 mg/day) upon entering this extension study. The dose could be increased (after at least 13 weeks of treatment) or decreased (at any time at or after 2 weeks of treatment) by the Investigator in 100-mg increments or decrements. The maximum allowable dose was 300 mg/day (or in those countries where limited by a Competent Authority or Ethics Committee, 200 mg/day).
Trial: NCT02524652
Drug: Ropivacaine 0.5% 20 mLs
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.
Trial: NCT03650452
Drug: TAK-935
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-935 tablets or mini-tablets.
Trial: NCT01013909
Drug: Bifonazole spray once daily
RxNorm normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of one dose daily by means of an metered dose
Trial: NCT01013909
Drug: Bifonazole spray twice daily
RxNorm normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of two dose daily by means of an metered dose
Trial: NCT01013909
Drug: Lamisil Once
RxNorm normalized name: Lamisil
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One application of Lamisil Once
Trial: NCT02713230
Drug: bupivacaine liposome injectable suspension
RxNorm normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline
Trial: NCT02713230
Drug: bupivacaine liposome injectable suspension
RxNorm normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mL EXPAREL (bupivacaine liposome injectable suspension)
Trial: NCT02065947
Drug: lidocaine , adrenaline, ketamine bolus, midazolam
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
Trial: NCT02065947
Drug: sevoflurane and 50% oxygen in air
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03100942
Drug: Lanraplenib
RxNorm normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 30 mg tablet administered orally once daily
Trial: NCT03100942
Drug: Filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 1 x 200 mg tablet administered orally once daily
Trial: NCT03100942
Drug: Tirabrutinib
RxNorm normalized name: Tirabrutinib
DrugBank: Tirabrutinib (DB15227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 40 mg tablet administered orally once daily
Trial: NCT03100942
Drug: Lanraplenib placebo
DrugBank: Lanraplenib (DB14770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x tablet administered orally once daily
Trial: NCT03100942
Drug: Filgotinib placebo
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 1 x tablet administered orally once daily
Trial: NCT03100942
Drug: Tirabrutinib placebo
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x tablet administered orally once daily
Trial: NCT00964548
Drug: Dantrolene
RxNorm normalized name: Dantrolene
DrugBank: Dantrolene (DB01219)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.25 mg/kg IV once over 60 min
Trial: NCT00964548
Drug: Dantrolene
RxNorm normalized name: Dantrolene
DrugBank: Dantrolene (DB01219)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg IV once over 60 min
Trial: NCT00390000
Drug: vatalanib
RxNorm normalized name: Vatalanib
DrugBank: Vatalanib (DB04879)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00390000
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00638326
Drug: clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
Trial: NCT00638326
Drug: clopidogrel plus placebo
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
Trial: NCT03899194
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: escitalopram 10-20 mg/d
Trial: NCT01563562
Drug: Bardoxolone Methyl
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, Single dose
Trial: NCT00152815
Drug: antioxidant vitamin E
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 150 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 70 mg in 1 mL TOPICAL CREAM [Lancome Paris UV Expert Aquagel Defense 50 Plus Sunscreen Broad Spectrum SPF 50 Plus Primer and Moisturizer with Antioxidant Vitamin E]
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 800IU per day for 12 months
Trial: NCT00162305
Drug: BMS-512148
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 100 mg, Once daily, 14 days.
Trial: NCT00162305
Drug: BMS-512148
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 25 mg, Once daily, 14 days.
Trial: NCT00162305
Drug: BMS-512148
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 5 mg, Once daily, 14 days.
Trial: NCT02568033
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04686799
Drug: Doxycycline Hyclate 20 MG
RxNorm normalized name: doxycycline hyclate 20 MG
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive doxycycline 20 mg BID
Trial: NCT02568033
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02568033
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02568033
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02568033
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01462812
Drug: Sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan 20mg
Trial: NCT01675531
Drug: Targin
RxNorm normalized name: Targiniq
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single arm for Targin
Trial: NCT02745223
Drug: PresbiDrops (CSF-1)
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PresbiDrops (CSF-1) is a topical ophthalmic drug.
Trial: NCT01171547
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily over 5 days
Trial: NCT02577406
Drug: AG-221
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days
Trial: NCT02577406
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC
Trial: NCT02577406
Drug: Low-dose cytarabine (LDAC)
RxNorm normalized name: ethinyl estradiol
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC
Trial: NCT02577406
Drug: Intermediate-dose cytarabine (IDAC)
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
Trial: NCT03225924
Drug: Entospletinib
RxNorm normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
Trial: NCT03225924
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cycles of 21 days - 375mg/m²
Trial: NCT02083510
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03696758
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive intravenous metoprolol. Dose titrated 1-5 mg every 2 minutes to achieve goal heart rate of 55-65 beats per minute, or for subjects with a resting heart rate already at goal, titrated to achieve a 10-15% reduction in heart rate.
Trial: NCT03696758
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)
Trial: NCT00915005
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 mg/m2 by vein 1 time each week for 7 weeks.
Trial: NCT00915005
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 2 by vein 1 time each week for 7 weeks.
Trial: NCT00935142
Drug: [18F]VM4-037
DrugBank: VM4-037 (DB15319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus IV injection of \[18F\]VM4-037
Trial: NCT01836575
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed, 500 mg/m2 + Pretreatment \[dexamethasone + vitamin B12 + folic acid, as per pemetrexed label\] + Antiemetic therapy at investigator's discretion.
Trial: NCT01836575
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin \[Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle\].
Trial: NCT01649739
Drug: Levitra
RxNorm normalized name: Levitra
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: There is 2 dosage:10mg Twice daily and 20mg Twice daily
Trial: NCT03225924
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cycles of 21 days - 1.4mg/m²
Trial: NCT01835496
Drug: single 1500 mg dose of Ferriprox
RxNorm normalized name: Ferriprox
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
Trial: NCT02231658
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02231658
Drug: Lixisenatide
RxNorm normalized name: Lixisenatide
DrugBank: Lixisenatide (DB09265)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02364206
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03225924
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cycles of 21 days - 40mg/m²
Trial: NCT03841136
Drug: anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anlotinib 12mg PO QD CBP(AUC 5mg/mL/min，or DDP（75mg/m2）D1 etoposide（100mg/m2）D1\~D3
Trial: NCT02446730
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00107770
Drug: sodium phenylbutyrate
RxNorm normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: histone deacteylase inhibitor
Trial: NCT02196194
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04065230
Drug: Tenofovir Alafenamide Fumarate tablets
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.
Trial: NCT00377143
Drug: Warfarin Dosing
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03747224
Drug: ARO-ANG3
RxNorm normalized name: ARO-ANG3
DrugBank: ARO-ANG3 (DB17626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections
Trial: NCT03747224
Drug: sterile normal saline (0.9% NaCl)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calculated volume to match active treatment
Trial: NCT02834052
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle
Trial: NCT02834052
Drug: Poly-ICLC
RxNorm normalized name: Poly-ICLC
DrugBank: Hiltonol (DB17293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18
Trial: NCT01533935
Drug: Tiotropium + Olodaterol
RxNorm normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 2.5 mcg + olodaterol 5 mcg once daily
Trial: NCT01533935
Drug: tiotropium + Olodaterol
RxNorm normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium 5 mcg + olodaterol 5 mcg once daily
Trial: NCT01533935
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium
Trial: NCT01533935
Drug: Olodaterol
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olodaterol 5 mcg once daily
Trial: NCT00103194
Drug: lapatinib ditosylate
RxNorm normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT03071224
Drug: [18F]Florbetapir
RxNorm normalized name: [18F]Florbetapir
DrugBank: Florbetapir F-18 (DB09149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-946.
Trial: NCT03136705
Drug: Lanthanum Carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum Carbonate tablet
Trial: NCT03136705
Drug: Lanthanum Carbonate Placebo
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sugar pill manufactured to look like Lanthanum Carbonate tablet
Trial: NCT02146079
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule
Trial: NCT02855411
Drug: PF-04958242
RxNorm normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT01281852
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01281852
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01281852
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03587038
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 mg/m2
Trial: NCT01728584
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NMB will be induced by intravenous (IV) administration of a bolus dose of 0.45 mg/kg rocuronium. NMB will be maintained using rocuronium infusion or additional bolus doses as needed for the management of NMB to the targeted depth according to the assigned treatment condition. - Standard NMB - administration of neuromuscular blocking agent (NMBA) titrated to a depth of blockade at a targeted TOF ratio of 10% (range: TOF count 2-3 to TOF ratio of 20%). - Deep NMB - administration of NMBA titrated to a targeted depth of 1-2 Post Tetanic Counts (PTCs) (range: 1-5 PTC).
Trial: NCT01728584
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NMB will be reversed with IV administration of 2 or 4 mg/kg sugammadex (depending on the depth of NMB) according to the approved label for sugammadex.
Trial: NCT00856271
Drug: olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablets, once daily for 8 weeks
Trial: NCT00856271
Drug: losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsules, once daily for 8 weeks
Trial: NCT03965988
Drug: DHA
RxNorm normalized name: DHA
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docosahexaenoic acid
Trial: NCT01936285
Drug: Colchicine 2 mg loading dose; 0.5 mg bid for 5 days
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00050349
Drug: EPO906 epothilone B
RxNorm normalized name: Aza-epothilone B
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00080314
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
Trial: NCT04676659
Drug: TNK-tPA
RxNorm normalized name: TNK-tPA
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol
Trial: NCT02085239
Drug: Lidocaine Ropivacaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 8-10 ml of Lidocaine given by subcutaneous injection~* 8-10 ml of Ropivacaine given by subcutaneous injection
Trial: NCT02085239
Drug: Lidocaine alone
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00553059
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg IV 30 minutes prior to administration of chemotherapy
Trial: NCT00553059
Drug: dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg tablet by mouth three times a day beginning 30 minutes before chemotherapy
Trial: NCT00553059
Drug: palonosetron hydrochloride
RxNorm normalized name: Palonosetron Hydrochloride
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.25 mg IV 30 minutes prior to administration of chemotherapy
Trial: NCT00012337
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no